Home  »  Morning Brief   »  Why Veru Should Be On Your Radar Moving Forward...

Why Veru Should Be On Your Radar Moving Forward

Veru shares climbed higher to set a new high yesterday after the oncology biopharmaceutical company released encouraging results regarding a cancer drug that is being examined.

The company, based in Miami, develops drugs for breast and prostate cancers. The company reported that a prostate cancer treatment appeared quite effective and safe in Phase 2 clinical trial, conducted in patients with acute respiratory distress caused by Covid-19.

Top 5 Cheap Stocks to Own Right Now

While finding safe stocks with the potential for monster gains isn't always easy, we've found a few that could pay out well. In fact, within our report, "Top 5 Cheap Stock to Own Right Now", we have identified five stocks we believe could appreciate the most even if you just have $1,000 to invest.

Sign up here to get your free report now. .

Sponsored

Veru announced that VERU-111 showed an 82% reduced mortality or respiratory failure from almost 30 days after treatment as compared with patients who received a placebo.Dr. Mitchell Steiner told Jim Cramer of CNBC that his cancer medicine can be an anti-inflammatory medicine as well as an antiviral to treat the respiratory disease sometimes fatal.

Veru is on course to meet with the U.S. Food and Drug Administration, as part of its efforts to provide individuals with severe cases of Covid-19 with an opportunity to participate in Phase 3 clinical trial.

About 200 hospitalized patients at high risk of acute respiratory distress syndrome are expected to be part of this trial study.40 patients were included in the Phase 2 trial in five sites across the U.S.

Veru aims to complete the clinical phase in the fourth quarter by the end of this year. The company says it will seek funding from the Biomedical Advanced Research and Development Authority of the Department of Health and Human Services to meet supply needs in the U.S.

Leave a Comment

Your email address will not be published.

Is Coeur Mining Inc. (CDE) a Keeper?

Coeur Mining Inc. (NYSE:CDE) went down by -4.20% from its latest closing price compared to the recent 1-year high of $7.64. The company’s stock price

[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]